Investor List:

Top Pharmaceuticals Series B Investors in Seattle / Portland (14)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Pharmaceuticals investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Ling Wong, General Partner at Highbury Group
Ling Wong
Highbury Group·General Partner
Sweet spot: $10.0M
Range: $500K - $50.0M
Investors in San Francisco (CA), Investors in Seattle (WA)
Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in ClimateTech/CleanTech (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in Diagnostics (Series A), Investors in Health & Hospital Services (Series B), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Generative Tech/AI (Series A), Investors in BioTech (Series A), Investors in Health IT (Series B), Investors in Generative Tech/AI (Series B), Investors in Diagnostics (Series A), Investors in Consumer Health (Series B), Investors in Generative Tech/AI (Seed), Investors in BioTech (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Consumer Health (Series A), Investors in Consumer Health (Seed), Investors in Enterprise (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Generative Tech/AI (Series B), Investors in Enterprise (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Generative Tech/AI (Series B), Investors in Generative Tech/AI (Series A), Investors in Pharmaceuticals (Series B), Investors in Enterprise (Seed), Investors in ClimateTech/CleanTech (Series B), Investors in Generative Tech/AI (Seed), Investors in Generative Tech/AI (Series A), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Seed), Investors in Generative Tech/AI (Seed), Investors in Consumer Health (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series B), Investors in Digital Health (Seed), Investors in ClimateTech/CleanTech (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in Health & Hospital Services (Series B), Investors in Consumer Health (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Consumer Health (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Consumer Health (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed), Investors in ClimateTech/CleanTech (Series A), Investors in BioTech (Series A), Investors in Enterprise (Series B), Investors in ClimateTech/CleanTech (Seed), Investors in Seattle / Portland (Other Lists), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Enterprise (Series B), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in San Francisco Bay Area (Other Lists)
to see your intro paths to Ling
Photo of Steven Gillis, Managing Director at ARCH Venture Partners
Steven Gillis
ARCH Venture Partners·Managing Director
Sweet spot: $25.0M
Range: $50K - $150.0M
Investors in Seattle (WA)
to see your intro paths to Steven
Photo of Leen Kawas, General Partner at Propel Bio Partners
Leen Kawas
Propel Bio Partners·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Seattle (WA)
Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Medical Devices (Seed), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Seed), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Seed), Investors in Seattle / Portland (Other Lists), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A)
to see your intro paths to Leen
Photo of Nathan McDonald, Managing Partner at Keiretsu Capital
Nathan McDonald
Keiretsu Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Seattle (WA)
Investors in Cosmetics (Seed), Investors in Cosmetics (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Seed), Investors in Hardware (Series B), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Seed), Investors in Media/Content (Series B), Investors in Cosmetics (Series B), Investors in Consumer Internet (Series B), Investors in Hardware (Seed), Investors in Media/Content (Seed), Investors in Cosmetics (Seed), Investors in Consumer Internet (Seed), Investors in Medical Devices (Series B), Investors in Hardware (Series B), Investors in Pharmaceuticals (Series B), Investors in Media/Content (Series B), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Hardware (Seed), Investors in Seattle / Portland (Other Lists), Investors in Media/Content (Seed), Investors in Consumer Internet (Series B), Investors in Consumer Internet (Seed)
to see your intro paths to Nathan
Photo of Ari Nowacek, Principal at ARCH Venture Partners
Ari Nowacek
Sweet spot: $25.0M
Range: $50K - $150.0M
Investors in Seattle (WA)
to see your intro paths to Ari
Photo of Takaaki Tobaru, Partner at Remiges Ventures
Takaaki Tobaru
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA), Investors in Tokyo, Investors in Seattle (WA)
to see your intro paths to Takaaki
Photo of Linda Li, Venture Partner at Remiges Ventures
Linda Li
Remiges Ventures·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Seattle (WA), Investors in Boston (MA), Investors in Japan
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series A), Investors in Consumer Health (Series B), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Series B), Investors in Seattle / Portland (Other Lists), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A)
to see your intro paths to Linda
Photo of Luciana Borio, Venture Partner at ARCH Venture Partners
Luciana Borio
ARCH Venture Partners·Venture Partner
Sweet spot: $25.0M
Range: $50K - $150.0M
Investors in Seattle (WA), Investors in Dublin (Ireland), Investors in SF Bay Area (CA), Investors in Chicago (IL)
Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Consumer Health (Series A), Investors in Consumer Health (Series B), Investors in BioTech (Seed), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Medical Devices (Series B), Investors in Health IT (Series A), Investors in Medical Devices (Seed), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Medical Devices (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Medical Devices (Series A), Investors in Consumer Health (Series B), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Washington, D.C. (Other Lists), Investors in Consumer Health (Series A), Investors in Digital Health (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Consumer Health (Series B), Investors in Consumer Health (Seed), Investors in Seattle / Portland (Other Lists), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in Midwest (Other Lists), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series B), Investors in Consumer Health (Seed), Investors in Health IT (Series B), Investors in Digital Health (Seed), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in San Francisco Bay Area (Other Lists)
to see your intro paths to Luciana
Get new data & insights delivered to your inbox
Firms investing in this space